Five Prime Therapeutics (FPRX) Boosted to Hold by BidaskClub

Five Prime Therapeutics (FPRX) Boosted  to Hold by BidaskClub

BidaskClub upgraded shares of Five Prime Therapeutics (NASDAQ:FPRX) from a sell rating to a hold rating in a report published on Friday, October 19th.

Several other brokerages also recently commented on FPRX. Raymond James initiated coverage on Five Prime Therapeutics in a research note on Thursday, June 28th. They set a market perform rating for the company. Citigroup reduced their target price on Five Prime Therapeutics from $60.00 to $44.00 and set a buy rating for the company in a research note on Monday, August 20th. Wells Fargo & Co reduced their target price on Five Prime Therapeutics from $58.00 to $35.00 and set an outperform rating for the company in a research note on Thursday, August 9th. Zacks Investment Research downgraded Five Prime Therapeutics from a buy rating to a hold rating in a research note on Wednesday, June 27th. Finally, Wedbush boosted their price target on Five Prime Therapeutics from $17.00 to $19.00 and gave the company a hold rating in a research note on Friday, August 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $31.70.

Shares of NASDAQ:FPRX traded down $0.41 during trading on Friday, hitting $12.42. 111,386 shares of the company were exchanged, compared to its average volume of 421,320. The firm has a market capitalization of $456.48 million, a price-to-earnings ratio of -2.31 and a beta of 3.23. Five Prime Therapeutics has a fifty-two week low of $11.72 and a fifty-two week high of $45.97.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.99) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.29) by $0.30. Five Prime Therapeutics had a negative return on equity of 40.61% and a negative net margin of 206.02%. The firm had revenue of $7.58 million for the quarter, compared to analyst estimates of $5.87 million. As a group, equities research analysts forecast that Five Prime Therapeutics will post -4.02 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Five Prime Therapeutics by 1.0% during the 2nd quarter. FMR LLC now owns 5,281,363 shares of the biotechnology company’s stock valued at $83,498,000 after acquiring an additional 52,319 shares during the period. BlackRock Inc. lifted its position in shares of Five Prime Therapeutics by 7.9% during the 2nd quarter. BlackRock Inc. now owns 2,863,520 shares of the biotechnology company’s stock valued at $45,271,000 after acquiring an additional 210,031 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Five Prime Therapeutics by 14.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,189,654 shares of the biotechnology company’s stock valued at $18,808,000 after acquiring an additional 147,904 shares during the period. Victory Capital Management Inc. lifted its position in shares of Five Prime Therapeutics by 3.3% during the 2nd quarter. Victory Capital Management Inc. now owns 1,102,760 shares of the biotechnology company’s stock valued at $17,434,000 after acquiring an additional 35,670 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Five Prime Therapeutics by 6.7% during the 2nd quarter. Northern Trust Corp now owns 394,878 shares of the biotechnology company’s stock valued at $6,243,000 after acquiring an additional 24,838 shares during the period. Hedge funds and other institutional investors own 86.40% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Featured Story: How is the S&P 500 index different from the DJIA?

Related posts

Leave a Comment